trending Market Intelligence /marketintelligence/en/news-insights/trending/BkBz9-o7ysyYz3WQ9yaf0Q2 content esgSubNav
In This List

Vanda Pharmaceuticals, Apotex settle patent litigation over schizophrenia drug

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Vanda Pharmaceuticals, Apotex settle patent litigation over schizophrenia drug

Vanda Pharmaceuticals said it granted Apotex Inc. and Apotex Corp. a nonexclusive license to manufacture and sell a version of Fanapt in the U.S., effective Nov. 2, 2027.

The license agreement resolves Vanda's patent litigation against Apotex regarding the latter's abbreviated new drug application for its generic version of Vanda's Fanapt.

If Vanda obtains pediatric exclusivity for Fanapt before Nov. 2, 2027, the license, which is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, will be effective May 2, 2028.

Fanapt is used in the treatment of schizophrenia in adults.